FDA Approves AstraZeneca Blood Pressure Drug for Resistant Hypertension

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

Resistant hypertension is a severe form of high blood pressure that does not improve with standard medications.

New option for millions.Before this, patients with resistant hypertension had few effective alternatives after standard drugs failed. Now baxdrostat gives them a novel treatment that works through a different mechanism.
11 point average reduction.In clinical trials, baxdrostat lowered systolic blood pressure by 11 points more than a placebo over 12 weeks. This significant drop can directly reduce the risk of heart attack and stroke for patients who were previously stuck with dangerously high readings.
Targets root cause.The drug blocks aldosterone synthase, an enzyme controlling the hormone aldosterone. Unlike older drugs that manage symptoms, this targets a specific driver of resistant hypertension for more precise control.
FDA approved and accessible.With official U.S. approval, doctors can now prescribe baxdrostat immediately to appropriate patients. This regulatory milestone ensures the drug meets safety and efficacy standards, giving patients a trusted new option.

The U.S. Food and Drug Administration has approved a new treatment from AstraZeneca for adults with high blood pressure that does not respond to standard therapies. The drug, called baxdrostat, offers a novel option for patients with resistant hypertension, a condition that affects millions worldwide and significantly raises the risk of heart attack and stroke.

In clinical trials, baxdrostat reduced systolic blood pressure by an average of 11 points more than a placebo over 12 weeks. The drug works by blocking aldosterone synthase, an enzyme that controls the production of the hormone aldosterone. By lowering aldosterone levels, the treatment helps the kidneys remove excess sodium and water, relaxing blood vessels and reducing pressure on the heart.

Resistant hypertension is defined as blood pressure that remains above target despite the use of three or more antihypertensive medications. Approximately 10 to 15 percent of adults with high blood pressure have this form. For these patients, existing drug classes often fail to provide adequate control, leaving them vulnerable to long term cardiovascular damage. Baxdrostat is specifically designed for this hard to treat group and is taken as a once daily pill.

A Targeted Approach for a Stubborn Condition

The approval is based on two Phase 3 studies that enrolled more than 1,500 patients. Participants taking baxdrostat showed consistent reductions in blood pressure across different ages, genders, and racial backgrounds. The most common side effects included mild fatigue, headache, and a slight increase in potassium levels, which doctors can monitor with routine blood tests. Importantly, the drug did not raise the risk of serious kidney problems or dangerous drops in blood pressure.

For patients who have struggled with multiple medications and lifestyle changes without success, this approval provides a new pathway. Physicians now have an additional tool that targets a specific hormonal pathway often overlooked in standard treatment regimens. AstraZeneca plans to make baxdrostat available in pharmacies within the next few weeks, and patient assistance programs are expected to help with affordability.

Looking ahead, researchers are already studying whether baxdrostat could benefit patients with other conditions linked to aldosterone excess, such as heart failure and chronic kidney disease. The approval marks a meaningful step forward in personalized cardiovascular care, offering hope to those who have felt stuck in a cycle of ineffective treatments.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.